MNKD — MANNKIND CORP (Healthcare >> Biotechnology)
MNKD FAQ
What is MNKD's P/E ratio?
MANNKIND CORP (MNKD) currently trades at a P/E ratio of 125.68.
What is MNKD's ROE?
MANNKIND CORP reports a Return on Equity (ROE) of 40.40%.
What is MNKD's dividend yield?
MANNKIND CORP offers a dividend yield of 0.00%.
What is MNKD's Deepscope Quality Score?
Deepscope rates MNKD's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MNKD?
Deepscope's AI Timing Score for MNKD is 62 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MNKD belong to?
MANNKIND CORP is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.40
Price
-0.12
(-3.41%)
Day Change
|
|
|---|
MNKD Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 23) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ P/E tương đối cao
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...
| Yếu tố Chất lượng |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
3069
|
| Magic Formula Rank by ROE |
3069
|
| Magic Formula Rank by ROIC |
3029
|
| Price | 3.40 |
| PBV / Sector |
-18.37 / 4.63
|
| Earning Per Share | -0.07 |
| PE / Sector |
125.68 / 17.43
|
| PEG or PE/Growth / Sector |
-0.78 / 0.53
|
| Average 1M Daily Value |
19.65 M
GREAT
|
| Average 1W Daily Value |
17.40 M
GREAT
|
| Yếu tố Kỹ thuật |
|
57% |
| Sức khỏe tài chính |
|
37% |
| Khả năng kiếm lợi nhuận |
|
60% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-06 09:09:03 |
| Symbol | MNKD |
| Name | MANNKIND CORP |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 308.95 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,087.50 / 8,857.28 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1 Casper Street, Danbury, CT, United States, 06810
Phone: 818 661 5000
Website: https://mannkindcorp.com
Employees: 591
Sector: Healthcare >> Biotechnology
Description: MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google